Denis Cochonneau

This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Ogd2 Pharma, The University of Nantes, Centre National De La Recherche Scientifique. Active years: 2018-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Denis Cochonneau. Retrieved from https://idiyas.com/inventor/denis-cochonneau

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Nantes, FR (2018 - 2020)
Coueron, FR (2023)

Company Filing History:

The University of Nantes

patents

1 out of 5,383

Centre National De La Recherche Scientifique

patents

4. 1 out of 6

Institut De Cancerologie De L'ouest

patents

5. 1 out of 1,853

National Institute of Health and Medical Research

patents

where one patent can have more than one assignee

Years Active: 2018-2023

Loading Chart...

3 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11697689 - Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs (2023-07-11),

2. 10745489 - Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy forcancer (2020-08-18),

3. 10000575 - Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer (2018-06-19),

Title: Denis Cochonneau: Innovator in Cancer Therapeutics

Introduction

Denis Cochonneau is a notable inventor based in Nantes, France. He has made significant contributions to the field of cancer therapeutics, holding a total of 3 patents. His work focuses on innovative methods for targeting cancer stem cells and improving drug delivery systems.

Latest Patents

Cochonneau's latest patents include groundbreaking methods for utilizing antibodies against O-acetylated GD2 ganglioside. One patent discloses a method for delivering an anti-cancer agent into cells expressing the OAcGD2 ganglioside. Another patent outlines a new therapeutic and diagnostic strategy for cancer, involving an antibody that targets O-acetylated GD2 ganglioside for the treatment of cancer stem cells. This includes a pharmaceutical composition for treating cancer stem cells and methods for diagnosing and predicting treatment responses in patients.

Career Highlights

Throughout his career, Denis Cochonneau has worked with prominent organizations such as Ogd2 Pharma and Université de Nantes. His research has significantly advanced the understanding of cancer treatment and diagnostics.

Collaborations

Cochonneau has collaborated with esteemed colleagues, including Jean-Marc Le Doussal and Stephane Birkle. Their joint efforts have contributed to the development of innovative cancer therapies.

Conclusion

Denis Cochonneau's work exemplifies the impact of innovative thinking in the medical field, particularly in cancer treatment. His patents and collaborations highlight his commitment to advancing therapeutic strategies for cancer stem cells.

Profile summary based on public USPTO records.